Sunovion Announces Pivotal Study Results for Novel Drug Candidate Dasotraline Demonstrating Significantly Improved Attention Deficit Hyperactivity Disorder Symptoms in Children Compared to Placebo
Sunovion Announces Top-line Results from Studies Evaluating Dasotraline in Adults with Binge Eating Disorder and Attention Deficit Hyperactivity Disorder
Posted Conference Call for Acquisition of Tolero Pharmaceuticals, Inc. [Webcast]
Sumitomo Dainippon Pharma to Conduct Meropenem Business in Five Countries of South-East Asia and Hong Kong
Sunovion Enters into License Agreement for Three Approved Treatment Options for People with COPD in the U.S.
Teleconference Material (Acquisition of Tolero Pharmaceuticals, Inc.)
A Message from the President
Board of Directors and Executive Officers